<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17955167</article-id><article-id pub-id-type="pmc">3476156</article-id><article-id pub-id-type="publisher-id">417</article-id><article-id pub-id-type="doi">10.1007/s10194-007-0417-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original</subject></subj-group></article-categories><title-group><article-title>Frovatriptan <italic>vs.</italic> transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Guidotti</surname><given-names>Mario</given-names></name><address><phone>+39-031-324412</phone><fax>+39-031-324165</fax><email>mguidotti@valduce.it</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mauri</surname><given-names>Michela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barril&#x000e0;</surname><given-names>Caterina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guidotti</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Belloni</surname><given-names>Carlo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Neurologic Unit, &#x0201c;Valduce&#x0201d; General Hospital, Via Dante 11, I-22100 Como, Italy </aff><aff id="Aff2"><label>2</label>Gynecologic Unit, &#x0201c;Valduce&#x0201d; General Hospital, Como, Italy </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>10</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2007</year></pub-date><volume>8</volume><issue>5</issue><fpage>283</fpage><lpage>288</lpage><history><date date-type="received"><day>19</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag Italia 2007</copyright-statement></permissions><abstract id="Abs1"><p>Acute treatment of menstrual migraine (MM) attacks is often incomplete and unsatisfactory, and perimenstrual prophylaxis with triptans, oestrogen supplementation or naproxen sodium may be needed for decreasing frequency and severity of the attack. In this pilot, open-label, non-randomised, parallel group study we evaluated, in 38 women with a history of MM, the efficacy of frovatriptan (<italic>n</italic>=14) 2.5 mg per os or transdermal oestrogens (<italic>n</italic>=10) 25 &#x003bc;g or naproxen sodium (<italic>n</italic>=14) 500 mg per os once-daily for the short-term prevention of MM. All treatments were administered in the morning for 6 days, beginning 2 days before the expected onset of menstrual headache. All women were asked to fill in a diary card, in the absence of (baseline) and under treatment, in order to score headache severity. All women reported at least one episode of MM at baseline. During treatment all patients taking transdermal oestrogens or naproxen sodium and 13 out of the 14 patients (93%) taking frovatriptan had at least one migraine attack (<italic>p</italic>=0.424). Daily incidence of migraine was significantly (<italic>p</italic>=0.045) lower under frovatriptan than under transdermal oestrogens or NS. At baseline, the overall median score of headache severity was 4.6, 4.2 and 4.3 in the group subsequently treated with frovatriptan, transdermal oestrogens and naproxen sodium, respectively (<italic>p</italic>=0.819). During treatment the median score was significantly lower under frovatriptan (2.5) than under transdermal oestrogens (3.0) and naproxen sodium (3.9, <italic>p</italic>=0.049). This was evident also for each single day of observation (<italic>p</italic>=0.016). Among treatments differences were particularly evident for the subgroup of patients with true MM (<italic>n</italic>=22) and for frovatriptan vs. naproxen sodium. This study suggests that short-term prophylaxis of MM with frovatriptan may be more effective than that based on transdermal oestrogens or naproxen sodium.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Frovatriptan</kwd><kwd>Menstrual migraine</kwd><kwd>Transdermal oestrogens</kwd><kwd>Naproxen sodium</kwd><kwd>True menstrual migraine</kwd><kwd>Menstrually related migraine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Italia 2007</meta-value></custom-meta></custom-meta-group></article-meta></front><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Bigal</surname><given-names>M.E.</given-names></name><name><surname>Diamond</surname><given-names>M.</given-names></name><name><surname>Freitag</surname><given-names>F.</given-names></name><name><surname>Reed</surname><given-names>M.L.</given-names></name><name><surname>Stewart</surname><given-names>W.F.</given-names></name></person-group><article-title>AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000252808.97649.21</pub-id><pub-id pub-id-type="pmid">17261680</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslau</surname><given-names>N.</given-names></name><name><surname>Rasmussen</surname><given-names>B.K.</given-names></name></person-group><article-title>The impact of migraine: Epidemiology, risk factors, and co-morbidities</article-title><source>Neurology</source><year>2001</year><volume>56</volume><issue>[6Suppl1]</issue><fpage>4</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">11148226</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>J.L.</given-names></name></person-group><article-title>The influence of estrogen on migraine: a systematic review</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>1824</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1001/jama.295.15.1824</pub-id><pub-id pub-id-type="pmid">16622144</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Committee of the International Headache Society</collab></person-group><article-title>The International Classification of Headache Disorders</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><issue>[Suppl.1]</issue><fpage>1</fpage><lpage>160</lpage></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granella</surname><given-names>F.</given-names></name><name><surname>Sances</surname><given-names>G.</given-names></name><name><surname>Allais</surname><given-names>G.</given-names></name><name><surname>Nappi</surname><given-names>R.E.</given-names></name><name><surname>Tirelli</surname><given-names>A.</given-names></name><name><surname>Benedetto</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine referred to headache centres</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2004.00741.x</pub-id><pub-id pub-id-type="pmid">15315526</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allais</surname><given-names>G.</given-names></name><name><surname>Benedetto</surname><given-names>C.</given-names></name></person-group><article-title>Update on menstrual migraine: from clinical aspects to therapeutical strategies</article-title><source>Neurol Sci</source><year>2004</year><volume>25</volume><issue>[Suppl3]</issue><fpage>229</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1007/s10072-004-0292-6</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannix</surname><given-names>L.K.</given-names></name></person-group><article-title>Management of menstrual migraine</article-title><source>Neurologist</source><year>2003</year><volume>9</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1097/01.nrl.0000080952.78533.0a</pub-id><pub-id pub-id-type="pmid">12864931</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazi</surname><given-names>A.</given-names></name><name><surname>Silberstein</surname><given-names>S.D.</given-names></name></person-group><article-title>Hormone-related headache: pathophysiology and treatment</article-title><source>CNS Drugs</source><year>2006</year><volume>20</volume><fpage>125</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.2165/00023210-200620020-00004</pub-id><pub-id pub-id-type="pmid">16478288</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGregor</surname><given-names>A.</given-names></name></person-group><article-title>Migraine associated with menstruation</article-title><source>Funct Neurol</source><year>2000</year><volume>15</volume><issue>[Suppl3]</issue><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">11200785</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>V.</given-names></name></person-group><article-title>Targeted treatment strategies for menstrual migraine</article-title><source>J Fam Pract</source><year>2007</year><volume>56</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">17270114</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silberstein</surname><given-names>S.D.</given-names></name><name><surname>Elkind</surname><given-names>A.H.</given-names></name><name><surname>Schreiber</surname><given-names>C.</given-names></name><name><surname>Keywood</surname><given-names>C.</given-names></name></person-group><article-title>A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine</article-title><source>Neurology</source><year>2004</year><volume>63</volume><fpage>261</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">15277618</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>L.</given-names></name><name><surname>Mannix</surname><given-names>L.K.</given-names></name><name><surname>Landy</surname><given-names>S.</given-names></name><name><surname>Silberstein</surname><given-names>S.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Putnam</surname><given-names>D.G.</given-names></name><etal/></person-group><article-title>Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study</article-title><source>Headache</source><year>2001</year><volume>41</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.2001.111006248.x</pub-id><pub-id pub-id-type="pmid">11264684</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>L.C.</given-names></name><name><surname>Lipton</surname><given-names>R.B.</given-names></name><name><surname>Lay</surname><given-names>C.L.</given-names></name><name><surname>Solomon</surname><given-names>S.</given-names></name></person-group><article-title>A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>307</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">9674831</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moschiano</surname><given-names>F.</given-names></name><name><surname>Allais</surname><given-names>G.</given-names></name><name><surname>Grazzi</surname><given-names>L.</given-names></name><name><surname>Usai</surname><given-names>S.</given-names></name><name><surname>Benedetto</surname><given-names>C.</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Naratriptan in the short-term prophylaxis of pure menstrual migraine</article-title><source>Neurol Sci</source><year>2005</year><volume>26</volume><issue>[Suppl2]</issue><fpage>162</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1007/s10072-005-0435-4</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allais</surname><given-names>G.</given-names></name><name><surname>Bussone</surname><given-names>G.</given-names></name><name><surname>Lorenzo</surname><given-names>C.</given-names></name><name><surname>Mana</surname><given-names>O.</given-names></name><name><surname>Benedetto</surname><given-names>C.</given-names></name></person-group><article-title>Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects</article-title><source>Neurol Sci</source><year>2005</year><volume>26</volume><issue>[Suppl2]</issue><fpage>125</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1007/s10072-005-0424-7</pub-id><pub-id pub-id-type="pmid">15995829</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraud</surname><given-names>G.</given-names></name><name><surname>Spierings</surname><given-names>E.L.</given-names></name><name><surname>Keywood</surname><given-names>C.</given-names></name></person-group><article-title>Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan</article-title><source>Headache</source><year>2002</year><volume>42</volume><issue>[Suppl2]</issue><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.42.s2.7.x</pub-id><pub-id pub-id-type="pmid">12005301</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belsey</surname><given-names>E.M.</given-names></name><name><surname>Farley</surname><given-names>T.M.</given-names></name></person-group><article-title>The analysis of menstrual bleeding patterns: a review</article-title><source>Contraception</source><year>1988</year><volume>38</volume><fpage>129</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/0010-7824(88)90035-2</pub-id><pub-id pub-id-type="pmid">3048871</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>M.G.</given-names></name><name><surname>Meer</surname><given-names>Y.G.</given-names></name><name><surname>Pfeil</surname><given-names>J.P.</given-names></name><name><surname>Rijnierse</surname><given-names>J.J.</given-names></name><name><surname>Vos</surname><given-names>A.J.</given-names></name></person-group><article-title>Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test</article-title><source>Headache</source><year>1994</year><volume>34</volume><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1994.hed3402103.x</pub-id><pub-id pub-id-type="pmid">8163364</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sances</surname><given-names>G.</given-names></name><name><surname>Martignoni</surname><given-names>E.</given-names></name><name><surname>Fioroni</surname><given-names>L.</given-names></name><name><surname>Blandini</surname><given-names>F.</given-names></name><name><surname>Facchinetti</surname><given-names>F.</given-names></name><name><surname>Nappi</surname><given-names>G.</given-names></name></person-group><article-title>Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study</article-title><source>Headache</source><year>1990</year><volume>30</volume><fpage>705</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1990.hed3011705.x</pub-id><pub-id pub-id-type="pmid">2074162</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pradalier</surname><given-names>A.</given-names></name><name><surname>Vincent</surname><given-names>D.</given-names></name><name><surname>Beaulieu</surname><given-names>P.</given-names></name><name><surname>Baudesson</surname><given-names>G.</given-names></name><name><surname>Launay</surname><given-names>J.</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Rose</surname><given-names>C.</given-names></name></person-group><article-title>Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine</article-title><source>New Advances in Headache Research</source><year>1994</year><publisher-loc>London</publisher-loc><publisher-name>Smith-Gordon</publisher-name><fpage>129</fpage><lpage>132</lpage></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffenrath</surname><given-names>V.L.</given-names></name></person-group><article-title>Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine</article-title><source>Cephalalgia</source><year>1993</year><volume>13</volume><issue>[suppl]</issue><fpage>244</fpage><lpage>247</lpage></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smits</surname><given-names>M.G.</given-names></name><name><surname>Meer</surname><given-names>Y.G.</given-names></name><name><surname>Pfeil</surname><given-names>J.P.</given-names></name><name><surname>Rijnierse</surname><given-names>J.J.</given-names></name><name><surname>Vos</surname><given-names>A.J.</given-names></name></person-group><article-title>Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test</article-title><source>Headache</source><year>1994</year><volume>34</volume><fpage>103</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.1994.hed3402103.x</pub-id><pub-id pub-id-type="pmid">8163364</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacGregor</surname><given-names>E.A.</given-names></name></person-group><article-title>Oestrogen and attacks of migraine with and without aura</article-title><source>Lancet Neurol</source><year>2004</year><volume>3</volume><fpage>354</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(04)00768-9</pub-id><pub-id pub-id-type="pmid">15157850</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nappi</surname><given-names>R.E.</given-names></name><name><surname>Sances</surname><given-names>G.</given-names></name><name><surname>Brundu</surname><given-names>B.</given-names></name><name><surname>Taddei</surname><given-names>S.</given-names></name><name><surname>Sommacal</surname><given-names>A.</given-names></name><name><surname>Ghiotto</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval</article-title><source>Hum Reprod</source><year>2005</year><volume>20</volume><fpage>3423</fpage><lpage>3428</lpage><pub-id pub-id-type="doi">10.1093/humrep/dei260</pub-id><pub-id pub-id-type="pmid">16123089</pub-id></mixed-citation></ref></ref-list></back></article>
